What was filed
Aurobindo Pharma told the exchanges that its wholly owned subsidiary, Apitoria Pharma Private Limited, approved on 23 July 2026 the acquisition of an 80% stake in the contract research services business of A1 Biochem Group, on a debt-free and cash-free basis. The existing promoter of A1 Biochem will retain the remaining 20%.
The deal spans three entities: A1 Biochem Labs (India) Private Limited, the CRO business of A1 Biochem Research (India) Private Limited, and A1 Biochem Labs LLC, USA. On completion, the Indian entity will hold 100% of the US LLC and absorb the CRO business of the research arm. The consideration is in cash, completion is expected in 90–120 days subject to customary approvals, and the company said the transaction is not a related party transaction.
What A1 Biochem brings
Per the filing, A1 Biochem Group is a contract research organisation offering chemistry services — custom synthesis, medicinal chemistry, route scouting, analytical development and rapid process scale-up — primarily to pharmaceutical companies, biotechs and academic institutions in the USA. It runs two laboratories, in Wilmington, North Carolina and Hyderabad, and has exported services to the Netherlands, France and Japan among others.
The group is led by Dr. Rajendra Gadikota, who has more than 25 years' experience and will remain with the business after the acquisition. It employs 90-plus scientists across 50-plus fume hoods, with an existing base of over 50 clients and more than 800 completed projects in the USA.
Why it matters to a holder
Aurobindo framed the transaction as adding front-end research and development to Apitoria's existing large-scale API manufacturing, letting it create a dedicated Contract Research, Development and Manufacturing (CRDMO) platform for fuller-service, longer-lifecycle engagement with customers.
The company described the deal as complementary to its current API business rather than a move into a new line — a step earlier in the drug-development value chain rather than a departure from it.